Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00879489
Recruitment Status : Unknown
Verified April 2009 by Quantum Immunologics, Inc..
Recruitment status was:  Active, not recruiting
First Posted : April 10, 2009
Last Update Posted : February 25, 2011
University of South Alabama
Information provided by:
Quantum Immunologics, Inc.

Brief Summary:
The study uses a molecule or particle that is found only on cancer cells and is unique to cancer cells, as it is not detected on normal tissue. The molecule is known as "oncofetal antigen" or OFA. Because OFA is unique to cancer, the investigators feel OFA could be used to educate the patients' own defenses to more effectively fight the cancer on his or her own, that he or she is harboring. Although investigators found OFA to be present in large concentrations on all cancers, it was found to be especially abundant in breast cancers. Therefore, the investigators feel that this molecule would be a good target for stimulating patient defenses especially against breast cancer cells. To accomplish this, certain defense cells (immune cells)will be washed out from the patients' blood using a machine to which the patient is connected through two small cannula placed into veins located in the patients' arms those cells will be manipulated in the laboratory with artificially engineered OFA. These "reeducated" cells will be injected into the skin of patients. There will be a series of three skin injections in 4 week intervals. It is hoped that this treatment will convert the patients' defenses to a point that effective anti-cancer responses will be induced. Effectiveness of the treatment will be monitored with blood tests and assessment of the size of the cancers.

Condition or disease Intervention/treatment Phase
Breast Cancer Biological: Dendritic Cell Vaccination Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer
Study Start Date : May 2008
Estimated Primary Completion Date : March 2011
Estimated Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

Intervention Details:
  • Biological: Dendritic Cell Vaccination
    Autologous dendritic cells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally.

Primary Outcome Measures :
  1. Toxicity [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Response, Survival, Immunological Monitoring, Time to Disease Progression [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stage IV histologically proven breast cancer as defined by the AJCC Cancer
  • Staging Manual (6th edition 2003)
  • Patients must have completed one prior form of chemo and or radiation therapy for their disease and have failed to achieve remission.
  • There must be no clinical or radiographic signs of active brain metastases (CT of brain), or disease to the brain that is not considered controlled.
  • At least 4 weeks must have elapsed since chemotherapy or biological therapy and 2 weeks must have elapsed since therapy.
  • Female patients must be at least 18 years of age
  • Must be ambulatory with a ECOG performance status of <2
  • Must have common recall antigen DTH skin >2mm
  • Must have lab values as following ANC >1.5 x 109/L; platelets >100x109/L; Hb>9g/dL; creatinine<1.8 mg/dL or a creatinine clearance > 35 mL/min; total bilirubin < 2 x the upper limit of normal; AST and ALT < 2.5 x the upper limit of normal; albumin > 2.5 g/L
  • If of child bearing potential, must practice a reliable method of contraception at screening and must agree to continue this status until 6 months after receiving the last study vaccine injection. An HCG (pregnancy) test will be done monthly until the 3 vaccinations are complete.
  • Signed informed consent (see Appendix A, Clinical Protocol section 25.1) to be obtained according to ICH GCP guidelines before the patient is subjected to any extra diagnostic procedures performed for evaluation of eligibility for the trial.

Exclusion Criteria:

  • History of prior malignancy, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or cervical cancer stage 1B
  • Active infection requiring continuous use of antibiotic therapy
  • Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia
  • Autoimmune disease currently treated with steroids
  • Adverse reactions to vaccines such as anaphylaxis or other serious reactions, e.g. life-threatening reactions to medicine
  • History of immunodeficiency or autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis dermatomyositis, juvenile onset insulin dependent diabetes, or a vasculitic syndrome
  • Pregnancy or lactation
  • Any reason why, in the opinion of the investigator, the patient should not participate
  • Patients who have received cytotoxic anti-tumor therapy within 4 weeks prior to vaccination
  • Patients with active hepatitis (B,C) or HIV + individuals
  • Patients with more than four different lines of chemotherapy in the metastatic setting (excluding adjuvant chemotherapy)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00879489

Layout table for location information
United States, Alabama
Quantum Immunologics, Inc.
Mobile, Alabama, United States, 36608
Sponsors and Collaborators
Quantum Immunologics, Inc.
University of South Alabama
Layout table for investigator information
Principal Investigator: Paul O. Schwarzenberger, M.D.

Layout table for additonal information
Responsible Party: Charles Broes, CEO, Quantum Immunologics, Inc. Identifier: NCT00879489    
First Posted: April 10, 2009    Key Record Dates
Last Update Posted: February 25, 2011
Last Verified: April 2009
Keywords provided by Quantum Immunologics, Inc.:
Stage IV histologically proven breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Immunologic Factors
Physiological Effects of Drugs